The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Escudier et al., N Engl J Med 356(2):125-134 January 11, 2007.

Correction
PreviousPrevious
Volume 357:203 July 12, 2007 Number 2
NextNext

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Escudier, B.
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma . The last footnote of Table 2 (page 131) should have read "This rate is the sum of the percentages of patients with a complete response, a partial response, and stable disease for at least two cycles" rather than "This rate is the sum of the percentages of patients with a complete response, a partial response, and stable disease." The table has been corrected on the Journal's Web site at www.nejm.org. We regret the error.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.